Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HCW BiologicsHCWB -13.90%37 3-1 Month Momentum % is 163.87% as of Jul. 24, 2026. GuruFocus rates HCWB with a GF Score™ of 37/100 and a GF Value™ of $43.73 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 1,389 Biotechnology companies, HCW Biologics ranks better than 99.35% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-24), HCW Biologics's 3-1 Month Momentum % is 163.87%.
The industry rank for HCW Biologics's 3-1 Month Momentum % or its related term are showing as below:
HCWB's 3-1 Month Momentum % is ranked better than 99.35% of 1389
companies
in the Biotechnology industry
Industry Median: -12.73
vs HCWB: 163.87
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
HCW Biologics 3-1 Month Momentum % Related Terms
HCWB vs KAPA, IMNN, MTVA: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, HCW Biologics's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HCW Biologics 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HCW Biologics's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where HCW Biologics's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HCW Biologics (HCWB) has a 3-1 Month Momentum % of 163.87% as of Jul. 24, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on HCW Biologics and its competitors. According to the industry distribution chart, HCW Biologics ranks #9 out of 1389 companies in the Biotechnology industry, placing it in the top 0.59999999999999%.
Is HCW Biologics' 3-1 Month Momentum % too high?
HCW Biologics' current 3-1 Month Momentum % is 163.87%. Based on the distribution chart, HCW Biologics ranks #9 out of 1389 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, HCW Biologics has a GF Score™ of 37/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does HCW Biologics' 3-1 Month Momentum % compare to KAPA and IMNN?
According to the Biotechnology industry distribution chart, HCW Biologics ranks #9 out of 1389 companies for 3-1 Month Momentum %. This places HCW Biologics in the top 1% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on HCW Biologics and its competitors. HCW Biologics's current 3-1 Month Momentum % is 163.87%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HCW Biologics stock overvalued right now?
Based on GuruFocus' analysis, HCW Biologics (HCWB) is currently considered Possible Value Trap. The stock's GF Value™ is $43.73, compared to a current price of $2.88 — trading 93.4% below its estimated fair value. The current 3-1 Month Momentum % is 163.87%. HCW Biologics' overall GF Score™ is 37/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For HCW Biologics (HCWB), the current 3-1 Month Momentum % is 163.87% as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HCW Biologics (HCWB) Overvalued in 2026?
Based on GuruFocus' analysis, HCW Biologics stock appears to be undervalued.
The current stock price of $2.88 is trading 93.4% below its estimated GF Value™ of $43.73.
GuruFocus considers HCW Biologics to be Possible Value Trap.
Key valuation signals for HCWB:
3-1 Month Momentum %: 163.87%
GF Value™: $43.73 vs. price of $2.88 (93.4% below fair value)
No single metric tells the full story. See the HCWB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.
37GF Score
Get the complete analysis for HCWB
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HCWB has been successfully added to your 
